Bayer seeks approval for key heart drug in India

Pharmaceutical major Bayer has filed for Indian approval of its patented drug finerenone (Kerendia) to treat heart failure patients with LVEF of 40 and above. This move aims to address India's growing early-onset heart disease burden. Already approved for chronic kidney disease, Bayer anticipates approval for this new indication by year-end, following successful trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dVobQRg
via IFTTT

Read More

Global report says 40% of clinicians in India could be using AI in work

Over 40 per cent of Indian clinicians are now using AI for work, a threefold increase from last year, surpassing global adoption rates. Despite this rapid embrace and optimism, challenges like clinician burnout and institutional gaps in AI training and governance remain. Experts urge focused action to translate digital health policies into effective practice.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMGQCHV
via IFTTT

Read More

To what extent will Trump's tariffs impact Indian pharma? Govt assesses likely cost

Union Commerce ministry says US tariffs on pharma imports will not significantly impact India. India exports generic drugs, less affected by new rules. The nation is diversifying trade to counter US policy shifts. New free trade agreements with EFTA and the UK will boost marine exports. This strategy aims to broaden India's global market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTi4Nu3
via IFTTT

Read More

Managing diabetes early: A smart choice to consider

Early management of type 2 diabetes is crucial in India, where the disease poses a significant health and financial burden. Starting treatment promptly and adopting lifestyle changes can reduce long-term complications like heart disease and kidney failure. Proactive conversations with healthcare providers and adherence to treatment plans are essential for better health outcomes and reduced healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FVeCJXm
via IFTTT

Read More

Lupin subsidiary inks pact to acquire Netherlands-based VISUfarma

Lupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. The acquisition strengthens Lupin's specialty franchise. It will enter the ophthalmology market. The deal is expected to close by late 2025. This transaction will enhance Lupin's growth and margin profile.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CniF2oE
via IFTTT

Read More

'Indian generics safe, tariffs unwise': Indian pharma association hits back after US tariff concerns

India's pharmaceutical industry, through the IPA, strongly countered US concerns regarding the quality of generic medicines, warning that tariffs would jeopardize America's drug security and increase reliance on China. The IPA cited FDA reports and independent testing affirming Indian facilities' high standards, highlighting billions saved for the US healthcare system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WNlVZxP
via IFTTT

Read More

Veterinary vaccine firms form association for collaboration with policymakers

India's leading veterinary vaccine manufacturers, including Hester Biosciences and Indian Immunologicals, have formed the Veterinary Vaccine India Manufacturers Association (VVIMA). This new association will serve as the industry's collective voice, aiming to collaborate with policymakers to foster innovation and position India as a global hub for animal vaccine research and production. Rajiv Gandhi leads as President.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q6S4p0g
via IFTTT

Read More

Glenmark, Granules, Zydus recall products in US over manufacturing issues: USFDA

Indian drugmakers Glenmark, Granules India, Sun Pharma, Zydus, and Unichem are recalling various products in the US market due to manufacturing issues. These include CGMP deviations, failed impurity specifications, and label mix-ups, leading to Class I, II, and III recalls initiated from late August to mid-September. The USFDA reported these voluntary actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qt7GKTg
via IFTTT

Read More

Highs & Lows: Could the microdosing of psychedelics be a key missing piece in the mental health jigsaw?

A Netflix documentary highlights the re-evaluation of mind-expanding substances like LSD, once banned but now experiencing a scientific renaissance. New research, including a study on pharmaceutical LSD for anxiety, suggests these psychedelics could redefine mental health treatment. However, overcoming public demonization and ensuring rigorous scientific trials are crucial for their widespread acceptance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMRoBPA
via IFTTT

Read More

Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo

US President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BroP82Q
via IFTTT

Read More

Weight-loss drug Ozempic to debut in India soon

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive market against Eli Lilly's Mounjaro. Novo Nordisk's Wegovy also competes. The company's semaglutide patent expires next year, allowing generic versions. India has a large population with diabetes and obesity. Ozempic offers significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZgRvDCk
via IFTTT

Read More

Diabesity: It’s more than you think

The intertwined rise of obesity and type 2 diabetes, termed 'diabesity,' presents a significant health challenge in India. This condition, driven by complex factors beyond lifestyle, faces stigma hindering effective treatment. Indians, despite appearing thin, often have higher body fat, increasing their risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ezLwAQI
via IFTTT

Read More

Trump delivers another bitter tariff pill. Who’s set to bite the dust?

A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unless companies have manufacturing facilities in the country. This policy raises uncertainties about which drugs will be affected and challenges the Indian pharmaceutical sector, which significantly contributes to the U.S. market—supplying 47% of generics and saving the U.S. healthcare system $219 billion in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjyk36t
via IFTTT

Read More

Trump's 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

The Indian Pharmaceutical Alliance clarifies that Trump's proposed 100% tariff targets patented and branded drugs, not generics, potentially impacting a segment of Indian exports. While the immediate effect on Indian exports may be limited due to their focus on generics and existing US manufacturing presence, the industry is advised to prepare for future policy changes and explore advanced pharmaceutical opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ctv2JXp
via IFTTT

Read More

Meril’s Mizzo Endo 4000 sets a new benchmark in robotic surgery

Meril, an Indian medical device company, has launched the Mizzo Endo 4000, a next-generation surgical robotic system. This advancement aims to enhance surgical precision and accessibility across various specialties. The system features AI-powered 3D mapping, an open console, and 5G-enabled telesurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bj4wYEX
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug to treat depression, anxiety

Alembic Pharmaceuticals Ltd. announced it has secured final approval from the USFDA for its generic Paroxetine extended-release tablets, available in 25 mg and 37.5 mg strengths. These tablets are therapeutically equivalent to Apotex Inc's Paxil CR and indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hfOoZ9A
via IFTTT

Read More

HIV-prevention drug to cost $40 a year from 2027

The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9% - for low- and middle-income countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RF2o8l5
via IFTTT

Read More

HCA Healthcare to invest $75 mln to set up Global Capability Center (GCC) in Hyderabad

HCA Healthcare inaugurated its Global Capability Center in Hyderabad, investing USD 75 million by 2025. The center, spanning 400,000 square feet, will employ 3,000 professionals by 2026, focusing on IT, supply chain, and finance. This strategic hub aims to drive innovation and operational excellence, supporting HCA Healthcare's patient care in the US and UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qXJHxSn
via IFTTT

Read More

Tata 1mg likely to get $200 mn booster shot; Novo, CPPIB, Permira and ChrysCap line up

Novo Holdings, CPPIB, Permira, and ChrysCapital have shown interest in investing in Tata Group’s online pharmacy 1mg, which seeks up to $200 million for its next growth phase. The investors, however, consider the $1.25 billion 2022 valuation too high, proposing $750–800 million instead. Some also want board seats, which Tata is unwilling to offer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtG0F8J
via IFTTT

Read More

India’s liver-heart-diabetes triangle: Why acting early could save your life

In India's bustling cities like Mumbai, a concerning trend emerges as fatty liver disease, now termed MASLD, quietly rises alongside diabetes and heart disease. Sedentary lifestyles, poor diets, and lack of awareness contribute to its prevalence, even among those with normal weight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vZsWTFx
via IFTTT

Read More

Vidal Health and Serum Institute collaborate on HPV vaccine access

Vidal Health, in partnership with Serum Institute of India, will launch a digital platform on October 1, 2025, to streamline HPV vaccine access and promote cervical cancer prevention. The platform offers convenient appointment booking, digital consent, and certification, ensuring a cashless and paperless experience. This collaboration aims to improve vaccine delivery efficiency and awareness, supporting national healthcare efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X5jEeYA
via IFTTT

Read More

India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threat

Donald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatments are most vulnerable. India, the world's pharmacy, faces potential export losses. Analysts foresee price hikes and supply chain disruptions. Indian firms may struggle to absorb tariffs. The US aims to boost domestic drug production. This move risks higher drug prices for Americans.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GdbjFB0
via IFTTT

Read More

India’s unique diabetes profile: The Indian diabetes phenotype—why our bodies react differently

Diabetes is rapidly increasing in India, affecting over 101 million people, often manifesting differently than in the West. Indians tend to develop diabetes earlier, even at lower weights, due to a "thin-fat" body type and less muscle mass. Genetic predispositions, poor early-life nutrition, and sedentary lifestyles contribute to this alarming trend, with many unaware of their condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cF9BOZp
via IFTTT

Read More

Drug companies flag concerns over timeline for carrying out regulator's manufacturing rule

Small and medium pharmaceutical companies are appealing to the health minister, raising concerns about stringent manufacturing standards imposed by the central drug regulatory body. These associations fear that the abrupt implementation timeline will force many MSMEs to shut down due to financial constraints and inability to meet the new requirements, potentially leading to medicine shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Er6lSsU
via IFTTT

Read More

PE fund KKR closes third buy in Kerala, at Meitra Hospital

KKR, buoyed by its successful Max Healthcare exit, is expanding its hospital investments in South India. Its Kerala-based Baby Memorial Hospital (BMH) has acquired a majority stake in Meitra Hospital for ₹1,000-1,200 crore and is considering acquiring Star Care Hospital.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wRNYXId
via IFTTT

Read More

Rehabilitation: India's 'missing link' in healthcare

Experts at the IAPMR Mid-Term CME 2025 highlighted India's rehabilitation shortage, emphasizing that discharge is not the end of treatment. The lack of structured rehabilitation, inadequate insurance coverage, and the removal of PMR from the medical curriculum are contributing to delayed recovery and frequent readmissions. They advocate for mandatory rehabilitation protocols and increased awareness to improve patient outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N0Gu4Fn
via IFTTT

Read More

India push into global natural healthcare market, government research institutions develop new drugs

India's herbal healthcare sector is preparing for a new growth phase, as traditional medicine blends with modern science to produce validated, affordable, and globally competitive solutions. This momentum was on full display at the recently concluded two-day CSIR Startup Conclave, where research institutions, startups, and policymakers joined forces to demonstrate how herbal formulations are moving from laboratories to the marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3sZLo72
via IFTTT

Read More

"Transformative shift in India's healthcare": Pharma alliance lauds GST reforms ahead of implementation

The Indian Pharmaceutical Alliance lauds the upcoming GST reforms, effective Monday, as a transformative step towards affordable healthcare. Prime Minister Modi's initiative reduces GST on most medicines from 12% to 5%, with complete exemption for 36 critical life-saving drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JgbqhIT
via IFTTT

Read More

Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry

From September 22, medicines and medical devices in India will become cheaper under new GST rates, making healthcare more affordable, say industry experts. Most drugs’ GST drops from 12% to 5%, while 36 critical life-saving medicines are fully exempt. Tax slabs on insurance, glucometers, and spectacles are also rationalised, easing costs for patients and improving access to essential care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dsCrcVk
via IFTTT

Read More

Fermenta board approves sale of environmental solutions biz to subsidiary

Fermenta Biotech on Friday said its board has approved transferring its environmental solutions business to a wholly owned subsidiary on a slump sale basis, effective October 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gJwf19o
via IFTTT

Read More

Fire at subsidiary unit temporarily hits production: Aurobindo Pharma

Aurobindo Pharma reported a fire incident on September 18, 2025, at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit, causing temporary production disruption. The fire, contained with no casualties, impacted two out of nineteen lines, resulting in an estimated 3% reduction in monthly capacity. Refurbishment is underway, with operations expected to resume in a few weeks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aZvj2Ar
via IFTTT

Read More

PMO acts on pharma MSMEs 'crisis call'

The PMO has been alerted to potential medicine shortages and price increases due to stringent regulatory actions on pharmaceutical quality. The Federation of Pharma Entrepreneurs warns that many MSMEs face closure due to costly GMP upgrades, potentially impacting the supply of essential medicines and causing significant job losses. They are urging the government to extend the compliance deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gWrq3Yc
via IFTTT

Read More

Indian pharma sector to log 7-9% growth in FY26 despite US headwinds: ICRA

India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7iWKYxw
via IFTTT

Read More

Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator

Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of the company's pharma division at the Kothur location. While objectionable conditions were noted, the agency does not plan immediate regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8N9RW41
via IFTTT

Read More

India ranks among top contributors in reporting adverse events: Drugs Controller General of India

DCGI Dr. Rajeev Raghuvanshi highlighted India's leading role in global adverse event reporting during the 5th National Pharmacovigilance Week. The week-long campaign, themed 'Your Safety, Just a Click Away: Report to PvPI', aims to encourage ADR reporting through simplified digital platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3KpDS7x
via IFTTT

Read More

AstraZeneca's asthma drug fails 'smoker's lung' study

AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the severe lung disease. Despite this, AstraZeneca will analyze the data to understand the results better, while its rare disease drug Saphnelo succeeded in a lupus trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ZxtNuS
via IFTTT

Read More

'Nimesulide' may come with warning label

Indian drug regulators have mandated cautionary labels for nimesulide, restricting its use as a second-line treatment for patients 12 years and older after exhausting first-line options. The labels must warn against use during pregnancy, lactation, or by women planning pregnancy, as well as in patients with renal or hepatic impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jh9fwUT
via IFTTT

Read More

Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to treat conditions like knee osteoarthritis and sleep apnea. Clinical trials are planned to investigate the impact of CagriSema and amycretin on various obesity-related comorbidities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/js6zR2W
via IFTTT

Read More

Scheme to promote innovation in pharma, medtech sectors to be launched this month: Pharma Secretary

The government will soon launch a scheme to boost innovation in the pharmaceutical and medical technology sectors. The PRIP scheme has a financial outlay of Rs 5,000 crore. It will support research and development. The scheme aims to reduce reliance on imports. Three medical device parks are expected to be functional by early 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQu1WPy
via IFTTT

Read More

In major move, patent of Novartis' blockbuster cardiac drug revoked by India

The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decision paves the way for generic versions, potentially lowering treatment costs for Indian patients. Domestic pharmaceutical companies had challenged the patent, arguing it violated Section 3(d) of the Patents Act, which prevents 'evergreening'.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wnIFz8S
via IFTTT

Read More

Novo Holdings in talks to buy into Surya Hospitals

Novo Holdings is in exclusive discussions to acquire a 49% stake in Surya Hospitals, valuing the Mumbai-based chain at ₹1,000 crore. This potential deal highlights the increasing consolidation in India's hospital sector, driven by significant financial investor activity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OEvLf6z
via IFTTT

Read More

India’s heart-risk score in diabetes: Why every Indian must pay attention - A World Heart Month special

In India, individuals with diabetes face a significant risk of cardiovascular disease, necessitating proactive heart health management. Tools like the IDRS and QRISK3 Score help assess this risk, especially crucial given the early onset of heart disease in Indians. Vigilance through regular check-ups, lifestyle adjustments, and awareness during World Heart Month can significantly improve outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LUWedl6
via IFTTT

Read More

Roche Pharma partners with 10 govt hospitals to bolster clinical trial capabilities in India

Roche Pharma collaborates with ten government hospitals. The goal is to improve clinical trial capabilities across India. Nearly 400 professionals receive training based on global standards. This initiative helps bring innovations to India faster. It aligns with priorities to boost government site participation. The Advanced Inclusive Research Site Alliance is now active in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na8JtuQ
via IFTTT

Read More

Reckitt has joined hands with PATH-CHRI to Launch Dettol Banega Swasth India - Maternal and Child Health Tech Accelerator.

Reckitt, in collaboration with PATH-CHRI, has launched an accelerator to drive innovation in maternal and child health. Centred on the first 1,000 days of life, the initiative aims to improve outcomes and strengthen India’s progress toward Viksit Bharat @2047.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F7oCRBr
via IFTTT

Read More

Why Indians skip the flu vaccine despite risks

In India, the quadrivalent influenza vaccine (QIV) faces low uptake due to limited awareness and high costs, despite being recommended for vulnerable groups. While global guidelines promote annual flu shots, India's lack of inclusion in the Universal Immunization Programme contributes to poor vaccination rates. Experts emphasize that yearly vaccination is necessary, although not foolproof, to mitigate flu severity and complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t9xN64T
via IFTTT

Read More

Creador to buy 7% stake in pharma company La Renon

Creador, a Kuala Lumpur-based private equity firm, is set to acquire a 7% stake in La Renon Healthcare for ₹800 crore, valuing the Indian pharmaceutical company at nearly ₹11,000 crore. The transaction involves a partial stake dilution by the promoter family and Peak XV Partners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SIXkJNM
via IFTTT

Read More

Pharma exporters seek rollback of rule banning export of India-only drugs

A new regulation by India's drug authority, restricting the export of pharmaceuticals labeled "For sale in India only," is causing significant losses to exporters, estimated at $500 million, and limiting access to affordable medicines for patients abroad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKhdya9
via IFTTT

Read More

Cupid announces strategic investment in fragrance brand Mansam

Cupid Ltd, an Indian healthcare products manufacturer, has signed a term sheet to acquire a strategic stake in Mansam, a Saudi Arabian luxury fragrance brand. The investment, facilitated through a fund managed by GII Investment Management Limited, aims to expand Cupid's international presence and tap into new consumer-driven markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FE9vkby
via IFTTT

Read More

Biocon inaugurates first manufacturing facility in US

Biocon Ltd has inaugurated its first US manufacturing facility in Cranbury, New Jersey, operated by its subsidiary, Biocon Generics Inc. Following the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc in 2023, Biocon invested over USD 30 million to establish the plant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r8AKiHu
via IFTTT

Read More

Dr Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brand

Dr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and Vietnam. This strategic move allows Dr. Reddy's to broaden its presence in the anti-vertigo market and reinforce its Central Nervous System portfolio. The company aims to extend Stugeron's reach across 18 key markets, aligning with its goal of reaching 1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ipQhes9
via IFTTT

Read More

Delhi HC stops drug body from taking action against IndiaMart

The Delhi High Court has temporarily blocked the CDSCO from pursuing criminal action against IndiaMart for allegedly listing unapproved medicines. This decision follows complaints regarding the online marketplace listing drugs like Crysvita, Oxbryta, and Jynneos, which are not approved for sale in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nzouJ3S
via IFTTT

Read More

Indian hospitals to raise IT innovation spend by 25% in 3 years: Report

Indian hospitals are poised to significantly increase their IT innovation spending, with a large portion of healthcare providers already dedicating a substantial part of their IT budgets to digital advancements. The focus will be on enhancing patient experience, improving clinical outcomes through technology, and enabling data-driven decision-making.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2npRztj
via IFTTT

Read More

WHO adds popular weight-loss drugs to essential medicines list

The World Health Organization has included Semaglutide and Tirzepatide, popular weight-loss drugs, in its Model List of Essential Medicines. This decision could significantly lower the prices of these medications in countries like India, where obesity rates have surged. The WHO aims to improve access and health outcomes by prioritizing those in need and encouraging generic competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B7hnD36
via IFTTT

Read More

Medicines may soon come with braille labels, audio QR codes

India's drug regulatory authority is exploring the addition of braille cards and voice-assisted QR codes on medicine strips to improve accessibility for visually impaired individuals. This initiative follows representations highlighting the difficulties faced by blind individuals in identifying medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u7VMezX
via IFTTT

Read More

Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report

A Systematix Research report indicates the Indian pharmaceutical industry is navigating uncertainty due to US tariffs, necessitating price increases, site transfers, and IP transfers. While raw material prices stabilize and companies explore new growth avenues, first quarter earnings were weak, with margin pressures in the US market. Firms cautiously evaluate inorganic growth and focus on OTC platforms amid these challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ONbHWxd
via IFTTT

Read More

The missed window: Why half of India’s people with diabetes learn too late

Many Indians unknowingly live with diabetes, missing the crucial early detection window. This delay, often due to subtle symptoms and lifestyle factors, leads to severe complications like kidney damage and heart issues. Early screening, awareness of risk factors, and regular check-ups are vital to managing diabetes and preventing long-term health problems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c1nQTlv
via IFTTT

Read More

Health experts alarmed by GST cut on beedis, demand uniform taxation

Health experts have criticised the government’s move to cut GST on beedis from 28% to 18% while keeping other tobacco products at 40%. They warned cheaper beedis, widely used by poor communities, could worsen India’s tobacco burden. Doctors stressed beedis are as harmful as cigarettes, urging uniform high taxes to curb use, protect vulnerable groups, and reduce health costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oL06EuC
via IFTTT

Read More

AstraZeneca to invest Rs 176 cr to expand GITC in Chennai

AstraZeneca is investing Rs 176 crore to expand its Global Innovation & Technology Centre in Chennai, marking its third investment in India in two years. This expansion will enhance the center's capabilities in AI, data analytics, and machine learning, supporting the development of next-generation medicines and digital healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aDime8O
via IFTTT

Read More

USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit

Aurobindo Pharma faces scrutiny. The US FDA inspected its Bachupally, Telangana plant. The inspection occurred between August 25 and September 5. Following the inspection, the US FDA issued a Form 483. The form contained eight observations. Aurobindo Pharma stated the observations are procedural. The company plans to respond to the US FDA within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXtOaJq
via IFTTT

Read More

Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drug

Glenmark Pharmaceuticals has commenced a Phase 3 clinical trial across multiple countries, including India, Russia, Brazil, and Mexico, for Envafolimab, a novel drug targeting third-stage non-small cell lung cancer (NSCLC). The trial aims to evaluate the drug's efficacy, safety, and other key parameters in NSCLC patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKbNkqL
via IFTTT

Read More

Type 2 diabetes triggering heart attacks in the 30s: Why India’s youth are at risk?

Type 2 diabetes is increasingly affecting young Indians, accelerating heart disease risks due to factors like genetics, visceral fat, and unhealthy lifestyles. Modern diets high in fats and sugars, coupled with sedentary habits and mental stress, significantly contribute to early heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xi5b1HV
via IFTTT

Read More

Pharma companies cheer lower drug prices, API tax gap stirs worry

Goods and Services Tax reforms are expected to reduce medicine prices in India. Experts say this will benefit patients and businesses. However, concerns exist regarding the higher tax rate on Active Pharmaceutical Ingredients. This could increase working capital pressure, especially for smaller companies. Provisional refunds may help mitigate these challenges. The government has reduced GST on several expensive medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rJcQTk6
via IFTTT

Read More

GST cut on drugs, medical devices to provide relief to patients: Industry players

The government is reducing GST on medicines and medical devices. Lifesaving drugs are exempt. This action will help patients and families. It will also make healthcare more affordable. Sudarshan Jain and Anil Matai welcome the changes. Ameera Shah and Shobana Kamineni also support the move. Himanshu Baid says it will improve access to medical technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WnEXcQ
via IFTTT

Read More

Crucial drugs to be more affordable after GST cut

The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart conditions, aiming to make healthcare more affordable. Key drugs like Risdiplam and daratumumab will now have zero GST, benefiting patients with spinal muscular atrophy and multiple myeloma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3D0ben
via IFTTT

Read More

Centre set to amend rules to simplify drug testing process

The Indian government is amending drug regulations to expedite the approval process for clinical trials and bioavailability/bioequivalence studies. These changes aim to reduce the statutory processing time for test license applications from 90 to 45 days. By simplifying procedures and reducing the number of license applications, the government anticipates faster drug development and approval, benefiting stakeholders and optimizing resource allocation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kijh5TH
via IFTTT

Read More

Alkem's Enzene powers into US with $70 m investment

Enzene Biosciences, an Alkem Labs subsidiary, has inaugurated a new US manufacturing plant. The facility is located in New Jersey. This venture represents a $70 million investment. It aligns with calls to boost local pharma manufacturing. Enzene's technology offers cost-effective drug production. The company currently employs 50 people. Enzene plans to increase its workforce to 200.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FW6hpHG
via IFTTT

Read More

Singapore-based firm proposes to acquire 25% in Welcure Drugs & Pharma

Welcure Drugs & Pharmaceuticals receives an offer from Telexcell Trade. Telexcell Trade, based in Singapore, plans to acquire a 25 per cent stake. The indicative price is Rs 20 per share. This investment aims to expand Welcure's global presence. The all-cash investment is estimated at Rs 52 crore. Welcure intends to invest in an agro-pharma research lab.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVTei6H
via IFTTT

Read More

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Lupin Ltd. secured USFDA approval for its generic risperidone extended-release injectable suspension, a treatment for schizophrenia and bipolar disorder. This marks Lupin's first product utilizing Nanomi BV's technology, benefiting from 180-day competitive generic therapies exclusivity. The drug, with estimated annual sales of USD 190 million, expands access to complex injectables for patients globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5cr3uk
via IFTTT

Read More

Caplin Point arm gets USFDA nod for milrinone lactate in 5 pc dextrose injection

Caplin Point Laboratories' arm, Caplin Steriles, secured USFDA approval for its generic milrinone lactate in 5% dextrose injection. Indicated for acute decompensated heart failure, the injection is a generic version of Sanofi Aventis' PRIMACOR. The US market for this injection reached approximately USD 11 million in sales for the year ending July 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRMWo3w
via IFTTT

Read More

Medical device manufacturers allowed to give free samples

Medical device companies in New Delhi can now give doctors free samples. There are rules for this. The sample's price must match what stockists pay. If the company bought the sample, that price counts. Company CEOs must ensure code compliance. Marketing costs must be disclosed yearly. This promotes ethical marketing and benefits both manufacturers and patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6CKwkI5
via IFTTT

Read More

India eyes Russia, Brazil, Netherlands for pharma export growth as US tariffs concerns linger

India is strategically planning to boost its pharmaceutical exports to Russia, the Netherlands, and Brazil, aiming to reduce reliance on the U.S. market due to tariff concerns. While the U.S. remains a crucial market, India seeks to diversify its export chain and increase market share in these growing regions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1YXg7P
via IFTTT

Read More

Glenmark launches generic cancer treatment drug in US

Glenmark Pharmaceuticals on Tuesday launched Eribulin Mesylate Injection, a generic cancer treatment, in the US through its subsidiary Glenmark Pharmaceuticals Inc., USA. The product, equivalent to Eisai’s Halaven Injection, will begin distribution this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GA9Vtaz
via IFTTT

Read More

Zydus launches VaxiFluTM trivalent influenza vaccine for flu protection in India

Zydus Lifesciences has introduced VaxiFlu, a trivalent influenza vaccine, in India. This vaccine aligns with WHO guidelines. It is for individuals aged six months and above. The vaccine contains updated strains for optimal protection. Flu remains a global health concern. It causes millions of severe illnesses and respiratory deaths annually. VaxiFlu aims to reduce vaccine-preventable diseases, especially in high-risk groups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HVIgytb
via IFTTT

Read More

Fortis Healthcare arm inks 15-year lease with RR Lifesciences to expand NCR reach

Fortis Healthcare's subsidiary, International Hospital Limited, has secured a 15-year lease. This agreement with RR Lifesciences Limited allows Fortis to operate and expand its facility in Greater Noida. Fortis will now have complete control over the 200-bed hospital, known as Fortis Hospital Greater Noida. The hospital aims to increase its capacity to approximately 250 beds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhIEa3Z
via IFTTT

Read More

The #WeightofDiabetes iceberg: Why the real burden lies beneath the surface

India faces a significant diabetes crisis, with millions undiagnosed, increasing the risk of heart disease. Early detection through screening and lifestyle changes like diet and exercise are crucial. Community programs and modern treatments offer hope for managing diabetes and improving long-term health outcomes, reducing the economic and health burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8tuywW5
via IFTTT

Read More

Govt launches advanced biomanufacturing hubs to boost bioeconomy, innovation

India has launched a network of advanced biomanufacturing hubs to boost its bioeconomy and drive innovation across sectors like health, agriculture and energy. This initiative, under the BioE3 Policy, provides state-of-the-art infrastructure and expertise to startups and researchers. India aims to achieve a USD 300 billion bioeconomy by 2030, positioning itself as a global leader in biotechnology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dE9MpFX
via IFTTT

Read More

Novo Nordisk ties up with Apollo Clinics for obesity management initiative

Novo Nordisk partners with Apollo Clinics to tackle obesity in India. The collaboration introduces a comprehensive obesity management programme across Indian cities. This initiative aims to provide structured care through multiple levels. The partnership focuses on equipping healthcare professionals with tools and support. The goal is to deliver personalized, evidence-based interventions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ok3qBwd
via IFTTT

Read More